A high frequency of MSH6 G268A polymorphism and survival association in glioblastoma.
Summary of "A high frequency of MSH6 G268A polymorphism and survival association in glioblastoma."
Abstract MSH6 (mutS homolog 6), one of the five key mismatch repair (MMR) genes, was found to play an important role in conferring resistance to alkylating agents - temozolomide (TMZ) in malignant glioma. This study aims to investigate whether genetic variations in MSH6 gene are associated with the survival outcomes in patients with malignant glioma. Each exon of the MSH6 gene was sequenced and single nucleotide polymorphism (SNP) analysis was performed using 74 tumor tissues from glioblastoma multiforme (GBM) patients. Among these patients, 54 patients received radiotherapy plus temozolomide (TMZ) treatment; 20 patients had radiotherapy only. The promoter methylation of O6-methylguanine methyltransferase (MGMT) was measured by MSP (methylation specific PCR). Literature mining and related data collection were done with NCBI and PubMed databases. Of the 74 GBM patients, 50% (n = 37) harbored MSH6 G268A polymorphism and no significant rates of other SNP or gene mutation across MSH6 exons were detected. The median OS was 15.6 months for who harbored the SNP and 12.6 months for SNP-negative patients (log-rank test: P = 0.324). The median OS for the MGMT promoter methylation group (n = 25) and non-methylation group (n = 29) of the 54 GBM patients treated with TMZ was 21.3 and 8.9 months respectively (P = 0.002). In conclusion, we identified a high frequency of MSH6 G268A polymorphism in MSH6 gene, which did not have a notable influence on survival for the malignant glioma patients with/without TMZ treatment.
1Dept. of Immunology, Harbin Medical University , 150081 Harbin , China.
This article was published in the following journal.
Name: The International journal of neuroscience
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/23057844
- DOI: http://dx.doi.org/10.3109/00207454.2012.738735
The aberrant constitutive activation of nuclear factor-κB (NF-κB) has been observed in glioblastomas, while NF-κB inhibitor alpha (NFKBIA) inhibits the NF-κB signaling pathway under several phys...
Half of all glioblastoma patients are at least 65 years old. The frequency and duration of hospitalization from disease- and treatment-related morbidity in this population are unknown.
MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study.
Promoter methylation of the O6-methylguanine-DNA-methyltransferase (MGMT) gene has been considered a prognostic marker and has become more important in the treatment of glioblastoma. However, reports ...
The Indian blood group antigens, In(a) and In(b), are clinically significant in transfusion medicine. However, antisera to type these antigens are difficult to obtain. The In(b) antigen is a high freq...
The optimal timing to initiate bevacizumab (BV) therapy for recurrent glioblastoma (GBM) is currently unclear. To address this issue, we examined progression-free survival (PFS) and survival time (ST)...
NovoTTF-100A is a device and Bevacizumab is a study drug that have both been approved by the FDA (Food and Drug Administration) for use as monotherapy in treating glioblastoma multiforme. ...
The primary goal of this study is to determine if a stem cell transplant in patients with newly diagnosed high risk CNS tumors (glioblastoma multiforme [GBM], high grade astrocytoma, pineo...
To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma
This is a study to see whether radiotherapy plus chemotherapy (Temozolomide) plus Dichloracetate (DCA) improves overall survival and offers better control of the disease in patients with n...
Investigational study to assess the overall response (OR) rate (CR + PR) of Imatinib mesylate and Hydroxyurea (Hydroxycarbamide) combination therapy on patients with recurrent glioblastoma...
Medical and Biotech [MESH] Definitions
Ventilatory support system using frequencies from 60-900 cycles/min or more. Three types of systems have been distinguished on the basis of rates, volumes, and the system used. They are high frequency positive-pressure ventilation (HFPPV); HIGH-FREQUENCY JET VENTILATION; (HFJV); and high-frequency oscillation (HFO).
Non-ionizing electromagnetic energy in the frequency range of 100 gigahertz to 10 terahertz which spans from the mid-INFRARED RAYS frequency to the high-frequency edge of the MICROWAVES band.
Electromagnetic waves with frequencies between about 3 kilohertz (very low frequency - VLF) and 300,000 megahertz (extremely high frequency - EHF). They are used in television and radio broadcasting, land and satellite communications systems, radionavigation, radiolocation, and DIATHERMY. The highest frequency radio waves are MICROWAVES.
A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population.
The use of focused, high-frequency sound waves to destroy tissue. It is sometimes used in conjunction with but is distinct from INTERVENTIONAL ULTRASONOGRAPHY.